Potent Vaccine Adjuvant Therapeutic

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$577,222.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI077229-01A2
Award Id:
93346
Agency Tracking Number:
AI077229
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
IMMURX Inc., 16 Cavendish Court, LEBANON, NH, 03766
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
781013615
Principal Investigator:
HILLARY WHITE
() -
Business Contact:
DAVID DELUCIA
() -
delucia@immurx.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have recently developed a proprietary form of immunization (co mbined TLR/CD40-agonist immunization) which elicits a T cell response exponentially greater than traditional vaccination methods, and produces potent protective T cell immune memory. The overall goal of these experiments is to develop a novel and potent va ccine platform for chronic infectious diseases, with a production cost and shelf life consistent with the needs of the third world. We therefore propose to produce and evaluate the generation and maintenance of protective cellular immunity following immuni zation with both protein-based and DNA-based combined TLR/CD40-agonist vaccine. Importantly we will evaluate these vaccines for their induction of protective immunity against aerosol challenge with TB. While CD40 agonists and TLR agonists have been used se parately in previous clinical settings, combining these agonists into a proprietary vaccine formulation is a novel, patented concept with no previous clinical exposure. Thus, the studies proposed below constitute an innovative vaccine platform with the pot ential for high impact as a prophylactic and/or therapeutic TB vaccine. PUBLIC HEALTH RELEVANCE: Project Narrative ImmuRx has developed a novel, patented vaccine platform capable of generating immunity 10 times greater than conventional vaccination methods . Preliminary data has shown this vaccine to be successful in protecting against both viral and bacterial infections and we will now examine how well the vaccine can protect against infection with TB, a representative of a globally significant chronic infe ctious disease. The results of these studies will lead to pre-IND studies in anticipation of clinical trials and subsequent commercialization to bring this powerful treatment to patients in need.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government